BioSpecifics Technologies Corp. Announces Board
Authorization
of up to $2.5 Million Stock Repurchase Program
LYNBROOK, NY – August 17, 2015 – BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in Europe, today announced that its Board of Directors has authorized an increase in the repurchase amount in the Company’s stock repurchase program, previously approved by the Board in December 2013, under which BioSpecifics is authorized to repurchase up to $2.5 million of its outstanding common stock. This decision reflects BioSpecifics’ positive outlook for the future, confidence it will remain profitable on an ongoing annual basis and its continued commitment to increasing value for its stockholders.
Pursuant to the repurchase program, BioSpecifics plans to repurchase stock through a broker in the open market, provided that the timing, actual number and price per share of the common stock to be purchased will be subject to market conditions, applicable legal requirements, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended, and various other factors. BioSpecifics intends to hold any reacquired stock in treasury. The repurchase program may be suspended or discontinued at any time by the Board of Directors. BioSpecifics has no obligation to repurchase common stock under the repurchase program.
As of June 30, 2015, BioSpecifics had 6,847,945 shares of common stock outstanding.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed injectable collagenase for twelve clinical indications to
date. Injectable collagenase is approved for marketing as XIAFLEX®
(collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of
adult Dupuytren's contracture patients with up to two palpable cords in the same
palm and for Peyronie's disease in men with a palpable plaque and a curvature
deformity of 30 degrees or greater at the start of therapy. XIAFLEX is marketed
in the U.S. by BioSpecifics' partner, Endo International plc (Endo), following
the acquisition of Auxilium Pharmaceuticals, Inc. by Endo. Endo has the
following partnerships outside the U.S. for XIAFLEX in Dupuytren's contracture
and Peyronie's disease; Swedish Orphan Biovitrum AB has marketing rights for XIAPEX® (the EU tradename for CCH) in 71
Eurasian and African countries, Actelion Pharmaceuticals Ltd. has marketing
rights in Canada, Australia, Mexico and Brazil, and Asahi Kasei Pharma
Corporation has marketing rights in Japan. CCH is in clinical development for
the treatment of several additional promising indications. Endo is managing the
clinical development of CCH for frozen shoulder syndrome and cellulite as well
as development in canine lipoma. BioSpecifics is currently managing the clinical
development of CCH for the treatment of human lipoma and preclinical development
for uterine fibroids. For more information, please visit www.biospecifics.com.
1
Forward Looking Statements
This release includes "forward-looking statements" within the
meaning of, and made pursuant to the safe harbor provisions of, the Private
Securities Litigation Reform Act of 1995. All statements other than statements
of historical fact, including statements regarding the Company's strategy,
future operations, future financial position, future revenues, projected costs,
prospects, plans and objectives of management, expected revenue growth, and the
assumptions underlying or relating to such statements, are "forward-looking
statements". The forward-looking statements in this Report include statements
concerning, among other things, whether BioSpecifics will achieve its corporate
goals and remain profitable on an ongoing basis; the plans for the repurchase of
stock and reacquired stock; and the suspension or discontinuation of the
repurchase program. In some cases, these statements can be identified by
forward-looking words such as “expect,” “likely,” “continue,” “estimates,”
“may,” "will,” “currently,” and “potential,” the negative or plural of these
words, and other similar expressions. These forward-looking statements are our
predictions based on our current expectations and our projections about future
events. There are a number of important factors that could cause our actual
results to differ materially from those indicated by such forward-looking
statements, including the ability of Endo and its partners to achieve their
respective objectives for CCH in their applicable territories; the uncertainties
inherent in the initiation of future clinical trials; Endo or any of its
partners modifying their respective objectives and/or allocating resources other
than to CCH; the potential market for CCH in a given indication being smaller
than anticipated; the potential of CCH to be used in additional indications and
the initiation, timing and outcome of clinical trials of CCH for additional
indications; the protection of the Company’s intellectual property portfolio;
the timing of regulatory filings and action; the receipt of any payments from
Endo; and other risk factors identified in our Quarterly Report on Form 10-Q for
the quarter ended June 30, 2015, our Annual Report on Form 10-K for the year
ended December 31, 2014 and our Current Reports on Form 8-K filed with the
Securities and Exchange Commission. All forward-looking statements included in
this presentation are made as of the date hereof, and we assume no obligation to
update these forward-looking statements.
Contact:
BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com
2